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Abstract:  Analbuminemia  is  a  rare  autosomal  recessive  disorder  manifested  by  the 
absence, or severe reduction, of circulating serum albumin (ALB). We report here a new 
case diagnosed in a 45 years old man of Southwestern Asian origin, living in Switzerland, 
on  the  basis  of  his  low  ALB  concentration  (0.9  g/L)  in  the  absence  of  renal  or 
gastrointestinal protein loss, or liver dysfunction. The clinical diagnosis was confirmed by 
a  mutational  analysis  of  the  albumin  (ALB)  gene,  carried  out  by  single-strand 
conformational polymorphism (SSCP), heteroduplex analysis (HA), and DNA sequencing. 
This screening of the ALB gene revealed that the proband is homozygous for two mutations: 
the insertion of a T in a stretch of eight Ts spanning positions c.1289 + 23–c.1289 + 30 of 
intron 10 and a c.802 G > T transversion in exon 7. Whereas the presence of an additional 
T in the poly-T tract has no direct deleterious effect, the latter nonsense mutation changes 
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the codon GAA for Glu244 to the stop codon TAA, resulting in a premature termination of 
the polypeptide chain. The putative protein product would have a length of only 243 amino 
acid  residues  instead  of  the  normal  585  found  in  the  mature  serum  albumin,  but  no 
evidence for the presence in serum of such a truncated polypeptide chain could be obtained 
by two dimensional electrophoresis and western blotting analysis.  
Abbreviations:  ALB,  serum  albumin  (protein);  ALB,  albumin  gene;  FcRn,  neonatal  
Fc receptor 
Keywords: human serum albumin; analbuminemia; heteroduplex analysis; single-strand 
conformation polymorphism; DNA sequence 
 
1. Introduction 
Congenital analbuminemia (MIM 103600) is a very rare autosomal recessive disorder [1]. In spite 
of the fact that the trait is readily detected by routine plasma electrophoretic analysis, only 51 cases 
have been so far reported world-wide in 43 families and are listed in the continuously updated Register 
of Analbuminemia Cases [2]. Thus, the incidence is less than one in one million for most populations, 
apparently without gender or ethnic predilection. However, fetal or neonatal death of siblings was 
frequently  observed  in  the  families  of  analbuminemic  subjects  [2,3].  This  seems  to  confirm  the 
hypothesis that only a few analbuminemic individuals survive past the neonatal state and that serum 
albumin (ALB) may play a crucial role in fetal development [4]. In contrast, during childhood and 
adult life, the analbuminemic individuals usually have surprisingly minimal findings, since the absence 
of  ALB  is  partially  compensated  for  by  an  increase  of  other  serum  proteins,  such  as  globulins, 
transferrin,  and  coagulation  factors  [1].  The  main  clinical  symptoms  include  mild  edema  and 
occasionally  chronic  fatigue  or  lipodystrophy,  especially  in  women,  while  the  most  common 
biochemical signs are gross hyperlipidemia with hypercholesterolemia and elevated LDL-cholesterol 
levels [1]. The finding of a low ALB concentration during routine serum electrophoresis, with normal 
liver function and no gastrointestinal or renal protein loss, suggests the clinical diagnosis. This needs to 
be confirmed by the molecular diagnosis, based on the identification of the causative mutation within 
the albumin (ALB) gene by DNA sequence analysis. In our continuing study of this defect, we report 
here  a  new  case  of  analbuminemia  observed  in  a  45-year-old  man  of  Lebanese  origin  living  in 
Switzerland and the identification of the causative mutation within the ALB gene.  
2. Results and Discussion 
2.1. Patient  
The patient is a 45-year-old man, born in Beirut, Lebanon, to parents of Syrian origin, living in 
Switzerland. The family comes from As Suwayda, a mainly Druze town located in Southwestern Syria, 
close to the border with Jordan. The parents are first degree cousins, and the patient is the second 
among ten children (seven brothers and three sisters), who all used to live in Lebanon, but have now Int. J. Mol. Sci. 2011, 12                       
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spread to different countries. The patient presented with severe lipodystrophy. He reported that since 
the age of 17 years he was suffering from edematous legs, for which he is currently under treatment by 
lymph drainage massage once in two weeks, plus tightly wrapped bandages. Among his brothers and 
sisters, only the eldest sister has also swollen legs, but, unlike our patient, she can only walk with 
significant  limitations.  As  far  as  he  can  remember,  his  mother  had  no  still-births  or  abortions  or 
problems getting pregnant. He reported an albumin level, measured by dye binding techniques, of  
16 g/L (normal reference range 37–52 g/L). His most relevant clinical chemistry data, determined at 
the Bern University Hospital, are summarized in Table 1. 
Table 1. Clinical laboratory test results on serum of the analbuminemic subject. 
Analyte  Proband  Units  Normal Reference Range 
albumin (relative)  1.7  %  56.8–66.2 
albumin (absolute)  0.9  g/L  35.0–52.0 
α1 globulins (relative)  12.3  %  3.0–5.3 
α1 globulins (absolute)  6.4  g/L  2.3–3.7 
α2 globulins (relative)  29.0  %  7.2–11.4 
α2 globulins (absolute)  15.0  g/L  5.2–8.6 
β globulins (relative)  25.5  %  8.7–12.7 
β globulins (absolute)  13.2  g/L  6.4–10.0 
γ globulins (relative)  31.5  %  11.0–18.7 
γ globulins (absolute)  16.3  g/L  3.8–7.5 
Total protein (absolute)  51,8  g/L  60.0–81.0 
Total cholesterol  8.43  mmol/L  <5.0 
LDL cholesterol  5.91  mmol/L  <3.0 
HDL cholesterol  1.87  mmol/L  >1.0 
Triglycerides  0.84  mmol/L  <2.0 
Calcium  1.94  mmol/L  2.20–2.65 
Phosphate  1.72  mmol/L  0.81–1.61 
The values are the average of 3 independent determinations. Albumin and the other plasma proteins 
were quantified by densitometric analysis of the serum protein electrophoresis pattern. All the other 
analytes were assayed by routine clinical laboratory procedures. % stands for percentage of the 
total protein content. 
The  patient  shows  severe  hypoalbuminemia  and  moderate  hypoproteinemia,  because  of  the 
compensatory  increase  of  the  globulin  fractions.  Also  a  western  blotting  analysis,  performed  as 
described  in  the  Experimental  Section,  confirmed  the  near  complete  absence  of  ALB  from  the 
proband’s  serum  (data  not  shown).  The  serum  lipid  profile  exhibits  moderate  dyslipidemia:  total 
cholesterol and LDL cholesterol are elevated, whereas HDL-cholesterol and triglycerides are in the 
normal range. On the basis of the results of the plasma protein electrophoresis and of the western 
blotting analysis congenital hypoalbuminemia was diagnosed in our patient, since other more common 
causes of low ALB levels, such as renal or gastrointestinal protein loss, or liver dysfunction, were 
ruled out. Int. J. Mol. Sci. 2011, 12                       
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2.2. Mutational Analysis  
To confirm this diagnosis at the molecular level, a mutational analysis of the ALB gene was carried 
out as described in the Experimental Section. Heteroduplex analysis (HA) revealed the presence of a 
mutation in the 406 bp long region amplified by using PCR primers A19B and A20C encompassing 
exon 10 and the intron9-exon10 and exon10-intron10 junctions [4]. DNA sequence of this fragment 
showed that the patient is homozygous for the insertion of a T in a stretch of eight Ts spanning positions 
c.1289  +  23–c.1289  +  30  of  intron  10  [5].  This  mutation,  reported  as  rs71217465  in  the  Single 
Nucleotide  Polymorphism  databank  at  NCBI,  was  previously  identified  in  another  analbuminemic 
subject,  a  girl  from  El  Jadida  (Morocco),  but  no  direct  deleterious  effect  could  be  ascribed  to  the 
presence of an additional T in this poly-T tract [6]. DNA sequence analysis of the remaining thirteen 
coding exons and their adjacent intron regions revealed the presence of an additional mutation in the 
region  encompassing  exon  7  and  the  intron6-exon7  and  exon7-intron7  junctions  that  escaped  our 
electrophoretic  analysis.  The  electropherogram  of  the  proband  (Figure  1B)  revealed  that  he  is 
homozygous for a c.802 G > T transversion in exon 7. 
Figure 1. Genomic DNA sequence electropherograms showing the mutation found in exon 7 
of the patient: (A) proband; (B) control for the wild type sequence. The arrows indicate the 
c.802 G > T transversion in exon 7. The patient is homozygous for the mutation. 
 
This nonsense mutation, that was also present in the analbuminemic girl from El Jadida [6], and, as 
such, is reported as pathogenic variation in the Single Nucleotide Polymorphism databank at NCBI 
(rs78340021), changes the codon GAA for Glu244 to the stop codon TAA, resulting in a premature 
termination  of  the  polypeptide  chain.  The  putative  protein  product  would  have  a  length  of  only  
243 amino acid residues (p.Glu268X) instead of the normal 585 found in the mature serum albumin, 
but no evidence for the presence in serum of such a truncated polypeptide chain could be obtained by 
two dimensional electrophoresis (data not shown) and western blotting analysis (Figure 2). Int. J. Mol. Sci. 2011, 12                       
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Figure 2. Western blotting of the patient’s serum showing the complete absence of the 
protein.ine 1, ALB; line 2, control serum; line 3, proband’s serum. 
 
Analbuminemia is thought to be associated with very few medical complications. However, an open 
question is whether analbuminemic individuals are at risk for atherosclerotic complications, considering 
most  of  them  are  known  to  have  high  cholesterol  levels.  Hypercholesterolemia  may  have  been 
responsible for some cases of premature coronary heart disease, although there are very few reports of 
patients  with  congenital  analbuminemia  who  have  had  long-term  follow-up  as  adults.  Therefore, 
although most patients with hereditary analbuminemia have not experienced premature atherosclerosis, 
treatment with statins appears to be recommended [7,8]. In view of the altered pharmacokinetics in 
patients  with  analbuminemia,  albumin-bound  drugs  should  be  administered  with  caution  and 
monitored carefully [8]. Our patient was treated for four weeks with atorvastatin (20 mg/day), but this 
statin was then stopped because he developed myopathy, one of the most common side effects of 
statins. He is currently being treated with another statin with lower plasma protein binding, such as 
pravastatin (40 mg/day). The proband also shows moderate hypocalcemia and hyperphosphatemia. 
ALB  is  the  principal  transport  and  depot  protein  for  calcium  in  blood  plasma  and  about  45%  of 
circulating calcium is bound to ALB [1]. Consequently, patients with a low ALB concentration are 
expected to have lower serum total calcium concentrations with biological active ionized calcium in a 
normal range [9].  
To date seventeen different mutations causing analbuminemia have been identified in the coding 
regions of the ALB gene and their intron–exon junctions in sixteen different subjects [2,3,10–12]: six 
nonsense mutations, four mutations affecting splicing, four frameshift/deletion, one frameshift/insertion, 
and a compound heterozygous nonsense/splice site mutation. The results show that analbuminemia is 
an  allelic  heterogeneous  disorder  caused  by  homozygous  or  compound  heterozygous  inheritance  
of defects. The molecular defects are located in eight different exons (3, 4, 5, 7, 8, 10, 11, and 12)  
and in three different introns (1, 6, and 11) [2,3,10–12]. Although those findings seem to suggest  
that analbuminemia is the result of widely scattered random mutations [10], the presence of regions in 
the  ALB  gene  that  are  prone  to  mutations  resulting  in  analbuminemia  is  still  an  open  question.  
The presence of such regions has been hypothesized in the exon 11-intron 11 junction and within  
exon 12 [3,12].  Int. J. Mol. Sci. 2011, 12                       
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The majority of those mutations are unique, i.e., they have been found in only a single individual or 
in the members of the same family. Exceptions to this rule are a c.412 C > T transition, found in two 
unrelated  individuals  (analbuminemia  Bethesda),  and  a  c.228_229delAT  (analbuminemia  Kayseri), 
found in twelve subjects of ten apparently unrelated families, that therefore appears to be the most 
frequent cause of analbuminemia so far identified [2,3 and other cases studied in our lab]. Here, we 
report  the  second  instance  of  a  c.802  G  >  T  transversion  that  was  previously  described  in  a  
five-year-old girl, the first child of a couple from El Jadida, Morocco [6]. 
As a consequence of the seventeen identified mutations, the protein product was predicted to range 
in length from 19 to 532 amino acid residues, although no evidence was found for the presence in 
serum of a truncated molecule [2,3]. A possible molecular explanation is that these putative proteins 
will partly or completely lack domain III of ALB, that has been shown to be crucial for binding to the 
neonatal Fc receptor (FcRn), which acts to recycle ALB to the serum, and therefore these truncated 
molecules cannot avoid lysosomal degradation [13]. Recent studies with a recombinant truncated ALB 
variant similar to a clinically observed splice mutant denoted Bartin, that lacks the whole of domain III 
except the first 25 amino acids, confirmed no detectable pH dependent FcRn binding [14].  
The analbuminemic individuals are prone to misdiagnosis or delayed diagnosis. In our patient the 
absence  of  severe  symptoms  and  the  presence  of  a  significant,  though  low,  amount  of  albumin 
probably contributed to delay the clinical diagnosis of analbuminemia or congenital hypoalbuminemia 
until the age of 45. The major pitfall in the diagnosis of analbuminemia is that the commonly used 
assays  for  albumin  quantification  in  serum  (based  on  dye-binding  techniques)  suffer  from  poor 
accuracy  in  presence  of  low  albumin  level,  usually  showing  an  overestimation  of  its  real  
amount [15,16]. Serum protein electrophoresis is widely available and usually is more reliable with 
low  serum  albumin  measurements,  revealing  the  near  complete  absence  of  an  albumin  band  
(0–3 g/L) [15,16]. Immunoassays of serum albumin are likely the most accurate and often produces 
near-zero albumin results that are consistent with the diagnosis of analbuminemia [15,16]. However, 
even  the  most  reliable  immunochemical  method,  invariably  shows  the  presence  of  non-zero 
concentrations of albumin [3]. For instance, in the original El Jadida patient plasma, albumin was 
“low”  by  protein  electrophoresis,  <10  g/L  by  a  routine  chemical  technique,  and  <6  mg/L  by  an 
immunoassay using polyclonal antibodies and kinetic nephelometry [6]. Whether this is attributable to 
weak unspecific reactions or is the result of a “leaky” splicing process allowing tiny quantities of 
mRNA to be formed [3] still remains an open question. Therefore the final diagnosis of this rare 
condition requires the identification of the causative mutation within the ALB gene.  
3. Experimental Section 
3.1. Immunoblotting 
Abundance of albumin was examined with the use of Western blot. Briefly, 5 µg of serum was 
loaded  on  a  10%  polyacrylamide/sodium  dodecyl  sulfate  gel  and  subjected  to  separation  by 
electrophoresis.  Proteins  were  electroblotted  onto  polyvinylidene  fluoride  membrane  (Hybond,  GE 
Healthcare).  Antibody  against  human  ALB  was  used  (Bethyl,  Montgomery)  as  well  as  a  positive Int. J. Mol. Sci. 2011, 12                       
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control for ALB (Baxter, Germany). Positive immunoreactivity was detected with chemiluminescence 
substrate (ECL detection reagent, GE Healthcare). 
3.2. Mutational Analysis 
The mutational analysis of the ALB gene was carried out following the principles outlined in the 
Declaration of Helsinki. After we obtained informed consent, we collected blood samples from the 
proband and extracted genomic DNA from whole blood. Fourteen genomic fragments of the ALB gene 
encompassing the fourteen coding exons and their intron-exon junctions [5] were PCR amplified using 
specific primer pairs as described by Watkins et al. [4]. Genomic DNA from two unrelated healthy 
volunteers was available as a control. PCR amplification and HA and SSCP analysis were performed 
as previously described [11,12,17]. In preparation for sequence analysis, 5 µL of PCR products were 
cleaned  up  by  ExoSAP-IT.  (USB  Corporation;  GE  Healthcare  EUROPE  GmbH).  After  digestion,  
2.5 µL of purified PCR products were subjected to typical sequencing reactions by adding 1 µL of 
BigDye Terminator (Applied Biosystems) and 5 pmol of primer in a final reaction volume of 10 µL. 
Cycle conditions consist in a rapid denaturation (96 °C for 10 s) and annealing/extension (60 °C for  
3 min) for 25 cycles, followed by a terminal extension at 72 °C for 6 min. Excess of dye terminators 
were removed by ethanol precipitation twice. Samples were electrophoresed on an automated DNA 
sequencing instrument (Applied Biosystems 3100), using 50 cm capillary arrays and POP-6 polymer. 
Data were analysed using the Sequencher software version 4.7 (Genecodes Corp.). 
3.3. Two-Dimensional Electrophoresis  
Two-dimensional polyacrylamide gel electrophoresis was performed using the IPG system [18]. 
The first dimension, isoelectric focusing, was carried out on laboratory-made gels, cast on GelBond 
with a 4–10 non-linear immobilized pH gradient obtained with Acrylamido buffer solutions (Fluka) 
and the separation was run in the Multiphor II horizontal system (Amersham Biosciences). The gel 
strips were then equilibrated with SDS, placed on top of vertical 10% gels, and the second dimension 
was carried out using a Mini PROTEAN II cell (Bio-Rad). The gels were stained with Coomassie blue. 
4. Conclusions 
The case here reported shows that analbuminemic individuals are prone to misdiagnosis or delayed 
diagnosis. Clinicians should consider a diagnosis of analbuminemia even when the clinical laboratory 
detects ALB levels higher than 10 g/L, because routine assays, based on dye binding techniques, suffer 
from very poor accuracy in presence of a low ALB amount, and also immunoassays and serum protein 
electrophoresis may reveal non-zero amounts of the protein. Our strategy, based on the combination of 
SSCP, HA, and DNA sequencing allows the molecular diagnosis of this rare disorder, that is always 
necessary because the presence of minute ALB amounts may have many causes other than a genetic 
lack  of  the  protein.  In  the  case  reported  here  the  causative  mutation  escaped  the  SSCP  and  HA, 
probably because of the large size of the mutated fragment (394 bp). As seen in the original El Jadida 
case, however, this mutation could be evidenced by SSCP after digestion of the appropriate restriction Int. J. Mol. Sci. 2011, 12                       
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enzyme [6]. The identification of the defects in the ALB gene causing analbuminemia will contribute to 
shed light on the molecular basis underlying the trait.  
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